PHAS News and Press, PhaseBio Pharmaceuticals Inc. From 05/16/22

Held successful Type B pre-biologics license application (BLA) meeting with U.S. FDA for future submission of BLA for bentracimab BLA submission for bentracimab is planned for early in the fourth quarter of 2022 and PhaseBio is preparing for commercialization in U.S., if appro...

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Financial Officer John Sharp will participate in a fireside chat at t...

Gainers: Momentus (MNTS) +49%. Trevi Therapeutics (TRVI) +49%. Sunshine Biopharma (SBFM) +34%. Werewolf Therapeutics (HOWL) +30%. System1 (SST) +27%. AppTech Payments (APCX) +22%. MiNK Therapeutics (INKT) +21%. Ikena Oncology (IKNA) +19%. Sprinklr (CXM) +18%. PhaseBio Pharmaceuticals (PHAS) +...

PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported complete results from a phase 2b trial of bentracimab to reverse the antiplatelet activity of ticagrelor in patients presenting with uncontrolled bleeding or in need of surgery. The study enrolled 205 older volunteers (50-80 years old)...

Results presented on April 2 nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71 st Annual Scientific Session (ACC.22) Trial achieved primary reversal endpoint in older volunteers Bentracimab was w...

PhaseBio Pharmaceuticals press release (NASDAQ:PHAS): Q4 GAAP EPS of -$0.90 misses by $0.32. Revenue of $0.58M misses by $1.39M. Cash and cash equivalents at December 31, 2021, were $41.8 million, compared to $28.1 million at December 31, 2020. Shares -5.83% AH. For further details see: ...

Achieved key clinical milestones for bentracimab program, with positive results from both the completed Phase 2b trial and interim analysis of the ongoing REVERSE-IT global Phase 3 trial Company remains on track to submit Biologics License Application (BLA) for bentracimab in ...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

PhaseBio Pharma (NASDAQ:PHAS) completed a campaign of commercial scale runs required for validating the manufacturing process for its lead drug candidate bentracimab. The company said the Process Performance Qualification (PPQ) campaign consisted of multiple commercial scale runs re...

Manufacturing of bentracimab drug substance and drug product Process Performance Qualification (PPQ) batches has been completed PhaseBio remains on track to submit bentracimab Biologics License Application (BLA) in mid-2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq:...